Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

• Published in: Nature medicine Vol. 13; no. 9; pp. 1102 - 1107
• Main Authors: Patil, Sandeep T, Zhang, Lu, Martenyi, Ferenc, Lowe, Stephen L, Jackson, Kimberley A, Andreev, Boris V, Avedisova, Alla S, Bardenstein, Leonid M, Gurovich, Issak Y, Morozova, Margarita A, Mosolov, Sergey N, Neznanov, Nikolai G, Reznik, Alexander M, Smulevich, Anatoly B, Tochilov, Vladimir A, Johnson, Bryan G, Monn, James A, Schoepp, Darryle D
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.09.2007; Nature Publishing Group
• Subjects: Amino acids; Animals; Antipsychotic Agents - therapeutic use; Antipsychotic Agents - toxicity; Antipsychotics; Benzodiazepines - therapeutic use; Biomedical and Life Sciences; Biomedicine; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Bridged Bicyclo Compounds, Heterocyclic - toxicity; Cancer Research; Care and treatment; Chemical properties; Clinical trials; Control; Cyclic S-Oxides - therapeutic use; Cyclic S-Oxides - toxicity; Disease Models, Animal; Double-Blind Method; Health aspects; Humans; Infectious Diseases; Innovations; letter; Medical research; Mental disorders; Metabolic Diseases; Molecular Medicine; Neurosciences; Neurotransmitter receptors; Neurotransmitters; Placebos; Plasticity; Receptors, Metabotropic Glutamate - drug effects; Receptors, Metabotropic Glutamate - physiology; Rodents; Schizophrenia; Schizophrenia - drug therapy; United States; Russia

Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. These pathological features manifest behaviorally as positive symptoms (including hallucinations, delusions and t...